

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding and managing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-169/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-169" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding and managing resistant/refractory hypertension" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding and managing resistant/refractory hypertension.">
            <meta name="og:description" content="Read the latest article version by Michael Doumas, Konstantinos P Imprialos, Manolis S Kallistratos, Athanasios J Manolis, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="23889">
            <meta name="article-id" content="21669">
            <meta name="dc.title" content="Recent advances in understanding and managing resistant/refractory hypertension">
            <meta name="dc.description" content="The management of resistant hypertension presents several challenges in everyday clinical practice. During the past few years, several studies have been performed to identify efficient and safe pharmacological and non-pharmacological options for the management of such patients. The Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2) trial demonstrated significant benefits with the use of spinorolactone as a fourth-line drug for the treatment of resistant hypertension over doxazosin and bisoprolol. In addition, recent data support that spironolactone may demonstrate superiority over central acting drugs in such patients, as well. Based on the European guidelines, spironolactone is recommended as the fourth-line drug option, followed by amiloride, other diuretics, doxazosin, bisoprolol or clonidine. &amp;nbsp;Among several device-based approaches, renal sympathetic denervation had fallen into hibernation after the disappointing results of the Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN) 3 trial. However, the technique re-emerged at the epicenter of the clinical and research interest after the favorable results of three sham-controlled studies, which facilitated novel catheters and techniques to perform the denervation. Significant results of iliac anastomosis on blood pressure levels have also been demonstrated. Nevertheless, the technique-related adverse events resulted in withdrawal of this interventional approach. Last, the sympatholytic properties of the carotid baroreceptor activation therapy were associated with significant blood pressure reductions in patients with resistant hypertension, which need to be verified in larger controlled trials. Currently device-based approaches are recommended only in the setting of clinical trials until more safety and efficacy data become available.">
            <meta name="dc.subject" content="resistant hypertension, spironolactone, doxazosin, bisoprolol, clonidine, renal sympathetic denervation, iliac anastomosis, carotid baroreceptor activation therapy">
            <meta name="dc.creator" content="Doumas, Michael">
            <meta name="dc.creator" content="Imprialos, Konstantinos P">
            <meta name="dc.creator" content="Kallistratos, Manolis S">
            <meta name="dc.creator" content="Manolis, Athanasios J">
            <meta name="dc.date" content="2020/03/09">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.21669.1">
            <meta name="dc.source" content="F1000Research 2020 9:169">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="resistant hypertension">
            <meta name="prism.keyword" content="spironolactone">
            <meta name="prism.keyword" content="doxazosin">
            <meta name="prism.keyword" content="bisoprolol">
            <meta name="prism.keyword" content="clonidine">
            <meta name="prism.keyword" content="renal sympathetic denervation">
            <meta name="prism.keyword" content="iliac anastomosis">
            <meta name="prism.keyword" content="carotid baroreceptor activation therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/03/09">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="169">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.21669.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-169">
            <meta name="citation_title" content="Recent advances in understanding and managing resistant/refractory hypertension">
            <meta name="citation_abstract" content="The management of resistant hypertension presents several challenges in everyday clinical practice. During the past few years, several studies have been performed to identify efficient and safe pharmacological and non-pharmacological options for the management of such patients. The Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2) trial demonstrated significant benefits with the use of spinorolactone as a fourth-line drug for the treatment of resistant hypertension over doxazosin and bisoprolol. In addition, recent data support that spironolactone may demonstrate superiority over central acting drugs in such patients, as well. Based on the European guidelines, spironolactone is recommended as the fourth-line drug option, followed by amiloride, other diuretics, doxazosin, bisoprolol or clonidine. &amp;nbsp;Among several device-based approaches, renal sympathetic denervation had fallen into hibernation after the disappointing results of the Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN) 3 trial. However, the technique re-emerged at the epicenter of the clinical and research interest after the favorable results of three sham-controlled studies, which facilitated novel catheters and techniques to perform the denervation. Significant results of iliac anastomosis on blood pressure levels have also been demonstrated. Nevertheless, the technique-related adverse events resulted in withdrawal of this interventional approach. Last, the sympatholytic properties of the carotid baroreceptor activation therapy were associated with significant blood pressure reductions in patients with resistant hypertension, which need to be verified in larger controlled trials. Currently device-based approaches are recommended only in the setting of clinical trials until more safety and efficacy data become available.">
            <meta name="citation_description" content="The management of resistant hypertension presents several challenges in everyday clinical practice. During the past few years, several studies have been performed to identify efficient and safe pharmacological and non-pharmacological options for the management of such patients. The Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2) trial demonstrated significant benefits with the use of spinorolactone as a fourth-line drug for the treatment of resistant hypertension over doxazosin and bisoprolol. In addition, recent data support that spironolactone may demonstrate superiority over central acting drugs in such patients, as well. Based on the European guidelines, spironolactone is recommended as the fourth-line drug option, followed by amiloride, other diuretics, doxazosin, bisoprolol or clonidine. &amp;nbsp;Among several device-based approaches, renal sympathetic denervation had fallen into hibernation after the disappointing results of the Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN) 3 trial. However, the technique re-emerged at the epicenter of the clinical and research interest after the favorable results of three sham-controlled studies, which facilitated novel catheters and techniques to perform the denervation. Significant results of iliac anastomosis on blood pressure levels have also been demonstrated. Nevertheless, the technique-related adverse events resulted in withdrawal of this interventional approach. Last, the sympatholytic properties of the carotid baroreceptor activation therapy were associated with significant blood pressure reductions in patients with resistant hypertension, which need to be verified in larger controlled trials. Currently device-based approaches are recommended only in the setting of clinical trials until more safety and efficacy data become available.">
            <meta name="citation_keywords" content="resistant hypertension, spironolactone, doxazosin, bisoprolol, clonidine, renal sympathetic denervation, iliac anastomosis, carotid baroreceptor activation therapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Michael Doumas">
            <meta name="citation_author_institution" content="2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, 54250, Greece">
            <meta name="citation_author_institution" content="VAMC and George Washington University, Washington, USA">
            <meta name="citation_author" content="Konstantinos P Imprialos">
            <meta name="citation_author_institution" content="2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, 54250, Greece">
            <meta name="citation_author" content="Manolis S Kallistratos">
            <meta name="citation_author_institution" content="Cardiology, Asklepeion General Hospital, Athens, Attiki, 16673, Greece">
            <meta name="citation_author" content="Athanasios J Manolis">
            <meta name="citation_author_institution" content="Cardiology, Asklepeion General Hospital, Athens, Attiki, 16673, Greece">
            <meta name="citation_publication_date" content="2020/03/09">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="169">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.21669.1">
            <meta name="citation_firstpage" content="169">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-169/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-169.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=23889 /> <input type=hidden id=articleId name=articleId value=21669 /> <input type=hidden id=xmlUrl value="/articles/9-169/v1/xml"/> <input type=hidden id=xmlFileName value="-9-169-v1.xml"> <input type=hidden id=article_uuid value=3adf96ce-7b56-49ff-a450-80da1f03d2b5 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding and managing resistant/refractory hypertension"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.21669.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.21669.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-169"
  },
  "headline": "Recent advances in understanding and managing resistant/refractory hypertension",
  "datePublished": "2020-03-09T09:20:59",
  "dateModified": "2020-03-09T09:20:59",
  "author": [
    {
      "@type": "Person",
      "name": "Michael Doumas"
    },    {
      "@type": "Person",
      "name": "Konstantinos P Imprialos"
    },    {
      "@type": "Person",
      "name": "Manolis S Kallistratos"
    },    {
      "@type": "Person",
      "name": "Athanasios J Manolis"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The management of resistant hypertension presents several challenges in everyday clinical practice. During the past few years, several studies have been performed to identify efficient and safe pharmacological and non-pharmacological options for the management of such patients. The Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2) trial demonstrated significant benefits with the use of spinorolactone as a fourth-line drug for the treatment of resistant hypertension over doxazosin and bisoprolol. In addition, recent data support that spironolactone may demonstrate superiority over central acting drugs in such patients, as well. Based on the European guidelines, spironolactone is recommended as the fourth-line drug option, followed by amiloride, other diuretics, doxazosin, bisoprolol or clonidine.  Among several device-based approaches, renal sympathetic denervation had fallen into hibernation after the disappointing results of the Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN) 3 trial. However, the technique re-emerged at the epicenter of the clinical and research interest after the favorable results of three sham-controlled studies, which facilitated novel catheters and techniques to perform the denervation. Significant results of iliac anastomosis on blood pressure levels have also been demonstrated. Nevertheless, the technique-related adverse events resulted in withdrawal of this interventional approach. Last, the sympatholytic properties of the carotid baroreceptor activation therapy were associated with significant blood pressure reductions in patients with resistant hypertension, which need to be verified in larger controlled trials. Currently device-based approaches are recommended only in the setting of clinical trials until more safety and efficacy data become available."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-169",
            "name": "Recent advances in understanding and managing resistant/refractory..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding and managing resistant/refractory... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=23889 data-id=21669 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21669.1" data-recommended="" data-doi="10.12688/f1000research.21669.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-169/v1/pdf?article_uuid=3adf96ce-7b56-49ff-a450-80da1f03d2b5" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-21669-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-21669-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-21669-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Doumas M, Imprialos KP, Kallistratos MS and Manolis AJ. Recent advances in understanding and managing resistant/refractory hypertension [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):169 (<a class=new-orange href="https://doi.org/10.12688/f1000research.21669.1" target=_blank>https://doi.org/10.12688/f1000research.21669.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-21669-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=21669 id=track-article-signin-21669 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21669?target=/articles/9-169">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23889 /> <input name=articleId type=hidden value=21669 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding and managing resistant/refractory hypertension</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Michael Doumas<sup>1,2</sup>,&nbsp;</span><span class="">Konstantinos P Imprialos<sup>1</sup>,&nbsp;</span><span class="">Manolis S Kallistratos<a href="https://orcid.org/0000-0002-8256-4218" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8256-4218</div><sup>3</sup>,&nbsp;</span><span class=""><a href="mailto:ajmanol@otenet.gr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Athanasios J Manolis</span></a><sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Michael Doumas<sup>1,2</sup>,&nbsp;</span><span class="">Konstantinos P Imprialos<sup>1</sup>,&nbsp;</span><span class="">Manolis S Kallistratos<a href="http://orcid.org/0000-0002-8256-4218" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8256-4218</div><sup>3</sup>,&nbsp;</span><span class=""><a href="mailto:ajmanol@otenet.gr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Athanasios J Manolis</span></a><sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 09 Mar 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.21669.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, 54250, Greece<br/> <sup>2</sup> VAMC and George Washington University, Washington, USA<br/> <sup>3</sup> Cardiology, Asklepeion General Hospital, Athens, Attiki, 16673, Greece<br/> <p> <div class=margin-bottom> Michael Doumas <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Konstantinos P Imprialos <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Manolis S Kallistratos <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Athanasios J Manolis <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=64850-60819></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=35474-60820></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The management of resistant hypertension presents several challenges in everyday clinical practice. During the past few years, several studies have been performed to identify efficient and safe pharmacological and non-pharmacological options for the management of such patients. The Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2) trial demonstrated significant benefits with the use of spinorolactone as a fourth-line drug for the treatment of resistant hypertension over doxazosin and bisoprolol. In addition, recent data support that spironolactone may demonstrate superiority over central acting drugs in such patients, as well. Based on the European guidelines, spironolactone is recommended as the fourth-line drug option, followed by amiloride, other diuretics, doxazosin, bisoprolol or clonidine. &nbsp;Among several device-based approaches, renal sympathetic denervation had fallen into hibernation after the disappointing results of the Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN) 3 trial. However, the technique re-emerged at the epicenter of the clinical and research interest after the favorable results of three sham-controlled studies, which facilitated novel catheters and techniques to perform the denervation. Significant results of iliac anastomosis on blood pressure levels have also been demonstrated. Nevertheless, the technique-related adverse events resulted in withdrawal of this interventional approach. Last, the sympatholytic properties of the carotid baroreceptor activation therapy were associated with significant blood pressure reductions in patients with resistant hypertension, which need to be verified in larger controlled trials. Currently device-based approaches are recommended only in the setting of clinical trials until more safety and efficacy data become available. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> resistant hypertension, spironolactone, doxazosin, bisoprolol, clonidine, renal sympathetic denervation, iliac anastomosis, carotid baroreceptor activation therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Athanasios J Manolis (<a href="mailto:ajmanol@otenet.gr">ajmanol@otenet.gr</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Athanasios J Manolis </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Doumas M <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Doumas M, Imprialos KP, Kallistratos MS and Manolis AJ. Recent advances in understanding and managing resistant/refractory hypertension [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):169 (<a href="https://doi.org/10.12688/f1000research.21669.1" target=_blank>https://doi.org/10.12688/f1000research.21669.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 09 Mar 2020, <b>9</b>(F1000 Faculty Rev):169 (<a href="https://doi.org/10.12688/f1000research.21669.1" target=_blank>https://doi.org/10.12688/f1000research.21669.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 09 Mar 2020, <b>9</b>(F1000 Faculty Rev):169 (<a href="https://doi.org/10.12688/f1000research.21669.1" target=_blank>https://doi.org/10.12688/f1000research.21669.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e191>Introduction</h2><p class="" id=d7928e194>The prevalence of resistant hypertension ranges from 5 to 30% on the basis of the definition used by relevant studies<sup><a href="#ref-1">1</a></sup>. However, the true prevalence of resistant hypertension after applying a strict definition and having excluded causes of pseudo-resistant hypertension is less than 10% of the patients with treated hypertension<sup><a href="#ref-1">1</a></sup>. Importantly, resistant hypertension is related with higher risk for cardiovascular morbidity and mortality, chronic kidney disease, and other hypertension-mediated target organ damage<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d7928e209>Based on the European guidelines, resistant hypertension is defined as the failure to reduce systolic or diastolic blood pressure (BP) levels (or both) below 140 and 90 mm Hg, respectively, despite treatment with optimal doses (or best-tolerated doses) of an appropriate therapeutic strategy with the triple combination of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker with a calcium channel blocker and a thiazide/thiazide-type diuretic. As stated in the guidelines, home or ambulatory BP measurements should be used to confirm inadequate BP control, and exclusion of pseudo-resistant hypertension and secondary hypertension is mandatory to establish the diagnosis<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d7928e216>In the previous European guidelines (2013), the use of mineralocorticoid receptor antagonists, amiloride, and the alpha-1 blocker doxazosin were considered for the management of resistant hypertension<sup><a href="#ref-3">3</a></sup>. During the past few years, several studies in resistant hypertension, and especially the spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2) trial<sup><a href="#ref-4">4</a></sup>, resulted in changes in the recommendations for the management of resistant hypertension. Specifically, the addition of “low-dose spironolactone to existing treatment, or the addition of further diuretic therapy if intolerant to spironolactone, with either eplerenone, amiloride, higher-dose thiazide/thiazide-like diuretic or a loop diuretic, or the addition of bisoprolol or doxazosin” is now recommended<sup><a href="#ref-1">1</a></sup>. Similarly, the consensus document of the American Heart Association for the management of resistant hypertension recommends the use of either spironolactone or eplerenone as a fourth-line agent, followed by a beta-blocker, a dual beta- and alpha-blocker, clonidine, or diltiazem<sup><a href="#ref-5">5</a></sup>. The purposes of this review are to report and critically discuss the findings of recent studies that resulted in a stronger recommendation for the treatment of resistant hypertension and to report treatments under investigation that could prove to be useful in such patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e238>Exclusion of pseudo-resistant hypertension</h2><p class="" id=d7928e241>The exclusion of pseudo-hypertension is of paramount importance for the establishment of an accurate diagnosis. BP is often measured inaccurately; wrong-sized cuffs, measurement of BP only once, placement the cuff over the patient’s clothes, and wrong position of the patient are common mistakes performed in everyday clinical practice<sup><a href="#ref-1">1</a></sup>. A 2016 study demonstrated that readings performed in a routine triage setting were higher than the readings performed by trained physicians and resulted in a misdiagnosis of uncontrolled resistant hypertension in 33% of the patients<sup><a href="#ref-6">6</a></sup>. Under-treatment is also a common cause of pseudo-resistant hypertension, and studies indicate that a lack of BP control is often attributable to the absence of treatment intensification<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d7928e256>Another important cause of pseudo-resistant hypertension is poor medication adherence. The recent Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension (SYMPATHY) trial examined drug adherence with the detection of drug concentrations in blood samples in patients with uncontrolled hypertension on three or more anti-hypertensive drugs or with documented intolerance to two or more of the four major anti-hypertensive drug classes; 16% were non-adherent and 52% were poorly adherent<sup><a href="#ref-8">8</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e266>Exclusion of other causes contributing to resistant hypertension</h2><p class="" id=d7928e269>Lifestyle factors such as excessive alcohol and salt intake contribute to the presence of resistant hypertension. Large amounts of alcohol consumption (three or more drinks per day) have an important dose-related effect on BP levels in both normotensive and hypertensive patients<sup><a href="#ref-9">9</a></sup>. Abstinence in heavy alcohol drinkers may decrease 24 hours systolic and diastolic ambulatory BP levels by up to 7.2 and 6.6 mm Hg, respectively<sup><a href="#ref-10">10</a></sup>. Usually, patients with resistant hypertension present an average sodium intake that exceeds 10 g per day<sup><a href="#ref-11">11</a></sup>. Salt not only increases BP levels but also blunts the anti-hypertensive effect of the BP-lowering drugs<sup><a href="#ref-12">12</a></sup>. In salt-sensitive patients (elders, African-Americans, and patients with chronic kidney disease), these effects are much more pronounced<sup><a href="#ref-13">13</a></sup>. Moreover, obesity and increased body mass index in general increase significantly BP levels<sup><a href="#ref-1">1</a></sup>. The mechanisms that induce hypertension in those patients include the activation of sympathetic nervous system and renin–angiotensin–aldosterone system and also insulin resistance and impaired sodium excretion<sup><a href="#ref-14">14</a></sup>. The adoption of current European Society of Cardiology/European Society of Hypertension guidelines on lifestyle changes may significantly decrease BP levels in those patients and contribute to BP control.</p><p class="" id=d7928e301>Finally, several drugs and substances may increase BP levels. Non-steroidal anti-inflammatory drugs (NSAIDs) represent probably the most common agents in terms of worsening BP control<sup><a href="#ref-1">1</a></sup>. The use of NSAIDs not only increases BP levels but also can blunt the effect of various anti-hypertensive drugs such as diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers<sup><a href="#ref-1">1</a></sup>. The hypertensive effect of NSAIDs is more pronounced in patients with chronic kidney disease<sup><a href="#ref-1">1</a></sup>. Other substances that can increase BP levels are decongestants and stimulant agents used for weight loss and also contraceptives, cyclosporine, erythropoietin, and cortisone that increase BP levels mainly through fluid retention. A proposed work-up for patients with resistant hypertension is shown in <a href="#f1">Figure 1</a>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/23889/f6fa6f81-632b-4755-9d0d-ae903d2ff3d5_figure1.gif"><img alt="f6fa6f81-632b-4755-9d0d-ae903d2ff3d5_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/23889/f6fa6f81-632b-4755-9d0d-ae903d2ff3d5_figure1.gif"></a><div class=caption><h3>Figure 1. Proposed work-up for patients with resistant hypertension.</h3></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e336>Recent advances in pharmacological therapy</h2><div class=section><a name=d7928e339 class=n-a></a><h3 class=section-title>Data from clinical studies of spironolactone versus adrenergic blockers</h3><p class="" id=d7928e344>The landmark PATHWAY-2 study found significant benefits with the use of spironolactone in patients with resistant hypertension on a standard three-drug therapy with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, amlodipine, and indapamide<sup><a href="#ref-4">4</a></sup>. The study was a double-blind four-way crossover study that assessed the use of spironolactone (25 or 50 mg) versus bisoprolol (5 to 10 mg), doxazosin (5 to 10 mg), or placebo. To exclude non-adherence, the study was monitored with pill count and measurement of serum angiotensin-converting enzyme activity. Spironolactone was superior to both active treatments and placebo, and mean reductions in BP were 8.70, 4.48, and 4.03 mm Hg with spironolactone, bisoprolol, and doxazosin, respectively. Importantly, about 60% of the spironolactone users achieved BP control versus 43.3% of the bisoprolol and 41.5% of the doxazosin users<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d7928e355>Apart from the beneficial effect of spironolactone in patients with resistant hypertension, the PATHWAY-2 study offered three important findings. First, despite the superiority of spironolactone over bisoprolol and doxazosin, the use of the latter two drugs was associated with significant reductions in BP compared with placebo. Thus, the European guidelines recommend the use of bisoprolol and doxazosin for the treatment of resistant hypertension when spironolactone is contraindicated or not tolerated<sup><a href="#ref-1">1</a></sup>. Second, uptitration of spironolactone dose from 25 to 50 mg resulted in a greater reduction in BP at week 12 of the study. The BP-lowering effect of spironolactone uptitration was higher compared with the corresponding increases in the dose of either bisoprolol or doxazosin (−3.86 mm Hg with spironolactone versus −0.88 mm Hg for doxazosin, −1.49 mm Hg for bisoprolol, and −0.68 mm Hg for placebo). Last, while spironolactone reduced BP levels irrespective of renin levels, an enhanced benefit in patients with suppressed renin levels was observed, and there was up to a 20 mm Hg reduction in home BP in patients with the lowest renin levels<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d7928e366>Important clinical information for the management of resistant hypertension arose from three recent substudies of the PATHWAY-2 trial. In the first substudy, the plasma aldosterone, renin, and aldosterone-to-renin ratio were assessed as predictors of home systolic BP response in 126 patients. Plasma aldosterone-to-renin ratio and plasma renin levels were found to be predictors of BP response to spironolactone. In the second one, the impact of each drug on the thoracic fluid content (an index of fluid retention) and vascular resistance was examined (226 patients). Thoracic fluid content was significantly reduced (by 6.8%) from baseline with spironolactone but not with the other active treatments. Given the overall outcomes of the PATHWAY-2 study, this finding supports the theory that patients with resistant hypertension are characterized by volume overload, secondary to aldosterone excess, explaining the greater benefits observed with spironolactone<sup><a href="#ref-1">1</a></sup>. In the third substudy, the effect of amiloride on systolic BP was examined in a 6- to 12-week open-label run-out phase, in which patients on spironolactone were crossed over from spironolactone to amiloride (146 patients). Amiloride use resulted in a remarkable reduction in BP levels of 20.4 mm Hg, comparable to the 18.3 mm Hg observed with spironolactone, suggesting that amiloride might be an effective alternative agent for these patients. Based on these findings, the European guidelines propose the use of amiloride as an alternative option if spironolactone is contraindicated or not well tolerated<sup><a href="#ref-15">15</a></sup>.</p></div><div class=section><a name=d7928e378 class=n-a></a><h3 class=section-title>Data from clinical studies of spironolactone versus central acting drugs</h3><p class="" id=d7928e383>Although concrete evidence supports the superiority of mineralocorticoid receptor antagonists over alpha- and beta-blockers for patients with resistant hypertension, there is a lack of evidence regarding the use of central acting drugs in such patients. In this setting, the recent Resistant Hypertension Optimal Treatment (ReHOT) study compared the impact of spironolactone and clonidine in 187 patients with resistant hypertension<sup><a href="#ref-16">16</a></sup>. BP control assessed with office and 24-hour ambulatory BP monitoring was similar across the two groups of patients. However, the 24-hour systolic and diastolic BP reduction and the daytime diastolic BP reductions observed with spironolactone were significantly greater than those observed with clonidine. Given the easier dosage scheme of spironolactone and the greater benefits in various ambulatory BP parameters, spironolactone seems to be a preferable option over clonidine<sup><a href="#ref-17">17</a></sup>.</p></div><div class=section><a name=d7928e395 class=n-a></a><h3 class=section-title>Meta-analytic data of mineralocorticoid antagonists versus other drug classes</h3><p class="" id=d7928e400>Important information emerged from meta-analytic data for the use of mineralocorticoid receptor antagonists in patients with resistant hypertension. In 869 patients from four trials, spironolactone as add-on therapy was associated with a reduction in BP of 16.67/6.11 mm Hg<sup><a href="#ref-16">16</a></sup>. A meta-analysis of 662 patients and five trials found that the addition of spironolactone in patients with resistant hypertension resulted in a reduction in office BP levels of 15.73/6.21 mm Hg compared with placebo, but compared with other drugs (beta-blocker, candesartan, or alpha methyldopa), spironolactone reduced home systolic BP by 4.5 mm Hg<sup><a href="#ref-18">18</a></sup>. In a meta-analysis of five studies and 553 patients with resistant hypertension, spironolactone reduced 24-hour, daytime, nighttime, and office BP by 10.50/4.09, 10.20/4.14, 10.02/3.21, and 16.99/6.18 mm Hg, respectively<sup><a href="#ref-19">19</a></sup>. Last, a meta-analysis of five studies and 755 patients with resistant hypertension found a greater reduction in systolic BP levels of 7.4 mm Hg (in the randomized studies) and 11.9 mm Hg (in the non-randomized studies) with mineralocorticoid receptor antagonists compared with other fourth-line options (bisoprolol, doxazosin, furosemide, or other renin–angiotensin system blockers)<sup><a href="#ref-20">20</a></sup>.</p><p class="" id=d7928e419>Collectively, accumulating evidence suggests that mineralocorticoid receptor antagonists are the optimal choice as the fourth-line option in patients with resistant hypertension, and data favor their use over central acting drugs, alpha- and beta-blockers. Most data come from studies with spironolactone. However, eplerenone may be considered as an alternative when adverse effects (such as gynecomastia or vaginal bleeding) are observed with spironolactone therapy<sup><a href="#ref-21">21</a></sup>, although strong data with eplerenone use are currently missing. Given the substantial fluid retention observed in these patients and the findings of the PATHWAY-2 study, amiloride is an alternative option, while treatment with doxazosin, bisoprolol, or clonidine may also be considered when either mineralocorticoid receptor antagonists or amiloride is contraindicated or adverse events occur.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e430>Interventional options for resistant hypertension</h2><p class="" id=d7928e433>Interventional approaches represent a novel potential addition on lifestyle interventions and pharmacological therapy for the management of resistant hypertension. The neurogenic mechanisms implicated in BP elevation have been the target of several interventional approaches such as renal sympathetic denervation (RSD) and carotid baroreceptor activation therapy<sup><a href="#ref-22">22</a>–<a href="#ref-24">24</a></sup>. The resistance of the arterial tree walls is another important factor contributing to the rise of BP. Recently, the creation of arteriovenous anastomosis between the distal iliac vein and artery to add a low resistance compartment to the arterial tree was investigated in patients with resistant hypertension<sup><a href="#ref-25">25</a></sup>.</p><div class=section><a name=d7928e447 class=n-a></a><h3 class=section-title>Renal sympathetic denervation</h3><p class="" id=d7928e452>The early RSD studies SYMPLICITY HTN-1<sup><a href="#ref-26">26</a></sup> and -2<sup><a href="#ref-27">27</a></sup> showed impressive reductions in BP and created high expectations for the future of the procedure in the hypertension treatment field. However, the first randomized sham-controlled study (SYMPLICITY HTN-3) failed to show any significant benefits of RSD over sham control in the reduction of both office and ambulatory BP in patients with drug-resistant hypertension<sup><a href="#ref-28">28</a></sup>, and the technique fell into hibernation. Although several pitfalls were identified, the incomplete denervation and lack of circumferential, four-quadrant sympathetic fiber interruption were the main factors pointed out as causes of the negative findings of the study<sup><a href="#ref-29">29</a></sup>. Three recent randomized sham-controlled studies used improved technologies and techniques to achieve optimal renal denervation and offered encouraging results.</p><p class="" id=d7928e471>The first one was the SPYRAL HTN-OFF MED trial, a randomized sham-controlled study of patients with untreated hypertension. Patients were randomly assigned to RSD of all accessible renal arterial vessels with the Symplicity Spyral multi-electrode catheter or the Symplicity G3 S (n = 38) or a sham procedure (n = 42). After 3 months, RSD resulted in significantly greater reductions in office and ambulatory BP levels compared with those of the sham control group (BP reduction differences of −7.7/−4.9 mm Hg and −5.0/−4.4 mm Hg in office and ambulatory BP, respectively). Importantly, no patient reported any safety concerns<sup><a href="#ref-30">30</a></sup>. Similar results were observed in the SPYRAL HTN-ON MED trial, a randomized sham control study (of patients with uncontrolled hypertension on one to three anti-hypertensive drugs) that used the same techniques described for SPYRAL-OFF MED. RSD resulted in a greater reduction in office and ambulatory BP compared with the sham technique group (BP reduction differences of −6.8/−3.5 mm Hg and −7.4/−4.1 mm Hg in office and ambulatory BP, respectively). No reports of renal artery stenosis or worsening of renal function were reported<sup><a href="#ref-31">31</a></sup>. The RADIANCE-HTN SOLO study was the third study that examined whether RSD performed with endovascular ultrasound reduces ambulatory BP in patients with hypertension in the absence of anti-hypertensive medication. After 2 months, significantly greater decreases in BP of −6.5/−4.1, −4.1/−1.8, and −7.1/−3.6 mm Hg in office, ambulatory, and home BP were reported with RSD compared with the sham control group<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d7928e486>A recent study assessed the efficacy of different ablation methods in reducing BP<sup><a href="#ref-33">33</a></sup>. Particularly, patients with resistant hypertension were assigned to either treatment with radiofrequency RSD of the main renal arteries, side branches, and accessories or an endovascular ultrasound-based RSD of the main renal artery. After 3 months, BP levels were significantly more reduced in the ultrasound ablation group compared with the radiofrequency ablation group of the main renal artery (−13.2 ± 13.7 versus −6.5 ± 10.3 mm Hg, respectively). Importantly, no significant difference was found between the radiofrequency ablation groups (−8.3 ± 11.7 mm Hg in the additional side branch ablation) or between the ultrasound and the side branch ablation groups, suggesting potential superiority of ultrasound over radiofrequency ablation of the main artery in reducing BP levels<sup><a href="#ref-33">33</a></sup>. However, larger studies are needed to confirm or dispute the superiority of one technique over the other. Up to then, no approach could be considered the preferred or first-choice option.</p><p class="" id=d7928e497>Collectively, these studies resurfaced the clinical and research interest for RSD in the management of resistant hypertension. Although more patients demonstrated BP reduction with RSD than with the sham procedure, in several study participants who underwent RSD, an increase in BP was noticed, suggesting that some patients are not eligible for RSD. The quest of patient eligibility requires the identification of reliable and accurate predictors of BP response, a very demanding step with unknown outcome. Studies with larger study populations and longer follow-up periods are needed to establish the safety and efficacy of the technique, and several such studies are either planned or being conducted. The results of these studies will either re-enforce the concept of RSD or put the final nail in the coffin of this interventional approach.</p></div><div class=section><a name=d7928e501 class=n-a></a><h3 class=section-title>Iliac vein and artery anastomosis</h3><p class="" id=d7928e506>The ROX CONTROL HTN study randomly assigned 83 patients with resistant hypertension to either pharmacological treatment plus placement of an arteriovenous coupler or pharmacological therapy alone. After 6 months, significant reductions in office and ambulatory systolic BP of 26.9 and 13.5 mm Hg were noted with the anastomosis device group, respectively. In contrast, such benefits were not observed in the control group (3.7 and 0.5 mm Hg, respectively). Similarly, a significant reduction in diastolic BP was reported with the device. However, implantation of the arteriovenous coupler was associated with ipsilateral venous stenosis in 29% of the patients, who received venoplasty or stenting<sup><a href="#ref-34">34</a></sup>. After 12 months, office BP and ambulatory BP were reduced by 25/20.8 and 12.6/15.3 mm Hg, respectively, suggesting that the technique might offer long-lasting benefits in BP levels. Nevertheless, the percentage of patients who presented venous stenosis increased to 33%, who were treated successfully with venous stenting<sup><a href="#ref-35">35</a></sup>. In conclusion, although iliac anastomosis showed promise in terms of efficacy, the safety concerns were significant and this approach was recently abandoned.</p></div><div class=section><a name=d7928e518 class=n-a></a><h3 class=section-title>Carotid baroreceptor activation therapy</h3><p class="" id=d7928e523>Carotid baroreceptor activation therapy is a device-based approach aiming to activate the baroreceptors that signal the brain to activate a sympatholytic response. Such approaches might be useful in conditions characterized by sympathetic overactivity, such as hypertension, heart failure, and arrhythmias<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. The potential benefits might be due to the reduction of heart rate (and thus cardiac workload and energy demands) and the manifestation of arterial dilation, which results in reduction of the peripheral resistance and enhancement of renal blood flow and natriuresis.</p><p class="" id=d7928e533>The Rheos Pivotal Trial assessed the impact of the Rheos system, a device that uses electrical impulses from a pulse generator to chronically activate the baroreflex at the carotid sinus, on BP levels in 265 patients with resistant hypertension. In the first group of patients, treatment was applied for the first 6 months, whereas in the second group, a delayed treatment initiation was implemented at the 6-month visit; 42% of patients in the first group versus 24% in the second group achieved systolic BP of less than 140 mm Hg at 6 months, and more than 50% in both groups had a systolic BP of less than 140 mm Hg at 12 months. However, the procedural safety endpoints of the study were not met since procedural complications occurred in 25% of the patients (transient or permanent nerve injury or general surgical complications)<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d7928e540>However, the same company developed a second-generation device of smaller size, the Barostim Neo, which uses a smaller electrode on the surface of only one of the sinuses, thus reducing the invasiveness of the procedure and extending the battery life and replacement period<sup><a href="#ref-39">39</a></sup>. The Barostim Neo System in the Treatment of Heart Failure/Barostim Hope for Heart Failure and the recent Baroreflex Activation Therapy in Patients with Heart Failure and a Reduced Ejection Fraction trials<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup> demonstrated significant benefits in the functional status, quality of life, and exercise capacity in patients with heart failure and reduced injection fraction. Importantly, these studies met the safety endpoints; thus, the device was granted approval by the US Food and Drug Administration<sup><a href="#ref-39">39</a></sup>. The device has also been approved in Europe for the management of resistant hypertension; the Barostim Neo trial demonstrated a persistent reduction in BP after 6 months (of a systolic BP of approximately 26 mm Hg) and an adequate safety profile<sup><a href="#ref-39">39</a>,<a href="#ref-42">42</a></sup>.</p><p class="" id=d7928e565>Overall, baroreflex activation therapy is approved for the treatment of resistant hypertension in Europe and for the treatment of heart failure with reduced ejection fraction in the US. However, it is more invasive than RSD, the safety of the procedure is not unequivocally proven, and thus it has not gained either wide application or general acceptance by hypertensive experts for the management of resistant hypertension.</p><p class="" id=d7928e569>The MobiusHD carotid bulb expansion device is an under-examination device that is used to reduce BP through stretching of the carotid artery at the bulb, which in turn activates the carotid baroreceptors. The Controlling and Lowering Blood Pressure with the MOBIUSHD (CALM-FIM_EUR) study recently reported pronounced reduction in BP levels of 24/12 mm Hg in office and 21/12 mm Hg in ambulatory BP with the use of the MobiusHD device in patients with resistant hypertension<sup><a href="#ref-43">43</a></sup>. Importantly, the device demonstrated an acceptable safety profile<sup><a href="#ref-43">43</a></sup>. Two other trials—the CALM-FIM_US<sup><a href="#ref-44">44</a></sup> and the Controlling and Lowering Blood Pressure with the MobiusHD (CALM-2)<sup><a href="#ref-45">45</a></sup> studies—are examining the use of the MobiusHD device in patients with resistant hypertension. The results of these studies are eagerly awaited to further clarify the efficacy and safety of this approach and strengthen its role in the management of resistant hypertension.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e593>Continuous positive airway pressure therapy and resistant hypertension</h2><p class="" id=d7928e596>Obstructive sleep apnea (OSA) is highly prevalent in patients with resistant hypertension<sup><a href="#ref-46">46</a>–<a href="#ref-51">51</a></sup>. It has been suggested that the increased fluid retention and consequent upper airway edema may explain the high prevalence of OSA in these patients<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>. In addition, central fluid accumulation during sleep seems to significantly contribute to the manifestation and worsening of OSA<sup><a href="#ref-54">54</a>–<a href="#ref-56">56</a></sup>. Treatment of OSA with continuous positive airway pressure (CPAP) in patients with resistant hypertension was found to induce a modest but significant reduction in BP levels. In a study of patients with resistant hypertension and OSA, CPAP treatment resulted in a reduction in ambulatory BP of 3.1/3.2 mm Hg, an effect that was even greater in patients more adherent to CPAP therapy (reduction in ambulatory BP of 4.4/4.1 mm Hg with at least 4 hours of CPAP treatment per night)<sup><a href="#ref-57">57</a></sup>. In contrast, a favorable impact of CPAP treatment on the prevention of cardiovascular events has not yet been demonstrated<sup><a href="#ref-58">58</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e631>Refractory hypertension</h2><p class="" id=d7928e634>The term refractory hypertension has been recently re-introduced and was included in the 2017 American guidelines for the management of hypertension<sup><a href="#ref-59">59</a></sup>. Refractory hypertension is defined as failure of BP control with the use of five or more anti-hypertensive drugs of different drug classes, including a long-acting thiazide diuretic, such as chlorthalidone, and a mineralocorticoid receptor antagonist<sup><a href="#ref-59">59</a></sup>. This novel type of uncontrolled hypertension seems to be rare, affecting less than 5% of the patients referred to a specialized clinic for uncontrolled hypertension. Furthermore, refractory hypertension was found to be more frequent in African-American, younger, and female patients<sup><a href="#ref-60">60</a>–<a href="#ref-62">62</a></sup>. There is evidence suggesting that the cause of treatment failure in patients with refractory hypertension, in contrast to resistant hypertension, is the increased sympathetic tone, rather than fluid retention, as indicated by the increased heart rate levels and urine norepinephrine excretion in such patients<sup><a href="#ref-60">60</a>–<a href="#ref-62">62</a></sup>. Therefore, intensification of diuretic therapy may not be effective, and sympatholytic agents or device-based therapy may be preferable<sup><a href="#ref-60">60</a>–<a href="#ref-62">62</a></sup>. However, data in such patients are still missing and studies are needed to identify optimal management options.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7928e669>Conclusions</h2><p class="" id=d7928e672>During the past few years, important data for the management of resistant hypertension have emerged. Most data support that mineralocorticoid antagonists (and especially spironolactone) present more favorable BP-lowering properties in patients with resistant hypertension compared with central acting drugs, alpha- and beta-blockers. In case of contraindications or adverse events, amiloride should be used as an alternative option followed by doxazosin, bisoprolol, or clonidine.</p><p class="" id=d7928e675>Several device-based approaches are being investigated, and recent RSD trials have rekindled interest in the interventional therapy of resistant hypertension. The few studies implementing carotid baroreceptor stimulation have shown favorable results, which need to be verified in controlled trials with a long follow-up period, while safety concerns need to be adequately addressed. Iliac anastomosis devices are no longer available in our therapeutic armamentarium. Overall, we are living in exciting times in the resistant hypertension field, and a lot of data, especially about the role of interventional approaches in the treatment of resistant hypertension, are eagerly expected in the near future.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d7928e682 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d8334>References</h2><div class="section ref-list"><a name=d7928e682 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733893992"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e689 class=n-a></a>Williams B, Mancia G, Spiering W, <i> et al.</i>: 2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>Eur Heart J.</i> 2018; <b>39</b>(33): 3021–104. <a target=xrefwindow id=d7928e700 href="http://www.ncbi.nlm.nih.gov/pubmed/30165516">PubMed Abstract </a> | <a target=xrefwindow id=d7928e703 href="https://doi.org/10.1093/eurheartj/ehy339">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733893992">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d7928e717 class=n-a></a>Daugherty SL, Powers JD, Magid DJ, <i> et al.</i>: Incidence and prognosis of resistant hypertension in hypertensive patients. <i>Circulation.</i> 2012; <b>125</b>(13): 1635–42. <a target=xrefwindow id=d7928e728 href="http://www.ncbi.nlm.nih.gov/pubmed/22379110">PubMed Abstract </a> | <a target=xrefwindow id=d7928e731 href="https://doi.org/10.1161/CIRCULATIONAHA.111.068064">Publisher Full Text </a> | <a target=xrefwindow id=d7928e735 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3343635">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d7928e744 class=n-a></a>Mancia G, Fagard R, Narkiewicz K, <i> et al.</i>: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Eur Heart J.</i> 2013; <b>34</b>(28): 2159–219. <a target=xrefwindow id=d7928e755 href="http://www.ncbi.nlm.nih.gov/pubmed/23771844">PubMed Abstract </a> | <a target=xrefwindow id=d7928e758 href="https://doi.org/10.1093/eurheartj/eht151">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725813579"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e767 class=n-a></a>Williams B, MacDonald TM, Morant S, <i> et al.</i>: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet.</i> 2015; <b>386</b>(10008): 2059–68. <a target=xrefwindow id=d7928e778 href="http://www.ncbi.nlm.nih.gov/pubmed/26414968">PubMed Abstract </a> | <a target=xrefwindow id=d7928e781 href="https://doi.org/10.1016/S0140-6736(15)00257-3">Publisher Full Text </a> | <a target=xrefwindow id=d7928e785 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4655321">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725813579">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734299250"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e799 class=n-a></a>Carey RM, Calhoun DA, Bakris GL, <i> et al.</i>: Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension.</i> 2018; <b>72</b>(5): e53–e90. <a target=xrefwindow id=d7928e810 href="http://www.ncbi.nlm.nih.gov/pubmed/30354828">PubMed Abstract </a> | <a target=xrefwindow id=d7928e813 href="https://doi.org/10.1161/HYP.0000000000000084">Publisher Full Text </a> | <a target=xrefwindow id=d7928e817 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6530990">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734299250">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d7928e831 class=n-a></a>Bhatt H, Siddiqui M, Judd E, <i> et al.</i>: Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. <i>J Am Soc Hypertens.</i> 2016; <b>10</b>(6): 493–9. <a target=xrefwindow id=d7928e842 href="http://www.ncbi.nlm.nih.gov/pubmed/27129931">PubMed Abstract </a> | <a target=xrefwindow id=d7928e845 href="https://doi.org/10.1016/j.jash.2016.03.186">Publisher Full Text </a> | <a target=xrefwindow id=d7928e849 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4905807">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d7928e858 class=n-a></a>Egan BM, Zhao Y, Li J, <i> et al.</i>: Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. <i>Hypertension.</i> 2013; <b>62</b>(4): 691–7. <a target=xrefwindow id=d7928e869 href="http://www.ncbi.nlm.nih.gov/pubmed/23918752">PubMed Abstract </a> | <a target=xrefwindow id=d7928e872 href="https://doi.org/10.1161/HYPERTENSIONAHA.113.01448">Publisher Full Text </a> | <a target=xrefwindow id=d7928e876 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4066303">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728770082"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e885 class=n-a></a>de Jager RL, van Maarseveen EM, Bots ML, <i> et al.</i>: Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. <i>Br J Clin Pharmacol.</i> 2018; <b>84</b>(1): 18–24. <a target=xrefwindow id=d7928e896 href="http://www.ncbi.nlm.nih.gov/pubmed/28815689">PubMed Abstract </a> | <a target=xrefwindow id=d7928e899 href="https://doi.org/10.1111/bcp.13402">Publisher Full Text </a> | <a target=xrefwindow id=d7928e903 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5736834">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728770082">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d7928e916 class=n-a></a>Chobanian AV, Bakris GL, Black HR, <i> et al.</i>: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. <i>Hypertension.</i> 2003; <b>42</b>(6): 1206–52. <a target=xrefwindow id=d7928e927 href="http://www.ncbi.nlm.nih.gov/pubmed/14656957">PubMed Abstract </a> | <a target=xrefwindow id=d7928e930 href="https://doi.org/10.1161/01.HYP.0000107251.49515.c2">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d7928e939 class=n-a></a>Aguilera MT, de la Sierra A, Coca A, <i> et al.</i>: Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. <i>Hypertension.</i> 1999; <b>33</b>(2): 653–7. <a target=xrefwindow id=d7928e950 href="http://www.ncbi.nlm.nih.gov/pubmed/10024322">PubMed Abstract </a> | <a target=xrefwindow id=d7928e953 href="https://doi.org/10.1161/01.hyp.33.2.653">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d7928e962 class=n-a></a>Nishizaka MK, Pratt-Ubunama M, Zaman MA, <i> et al.</i>: Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. <i>Am J Hypertens.</i> 2005; <b>18</b>(6): 805–12. <a target=xrefwindow id=d7928e973 href="http://www.ncbi.nlm.nih.gov/pubmed/15925740">PubMed Abstract </a> | <a target=xrefwindow id=d7928e976 href="https://doi.org/10.1016/j.amjhyper.2005.01.002">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d7928e986 class=n-a></a>He FJ, MacGregor GA: Effect of longer-term modest salt reduction on blood pressure. <i>Cochrane Database Syst Rev.</i> 2004; (3): CD004937. <a target=xrefwindow id=d7928e991 href="http://www.ncbi.nlm.nih.gov/pubmed/15266549">PubMed Abstract </a> | <a target=xrefwindow id=d7928e994 href="https://doi.org/10.1002/14651858.CD004937">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d7928e1003 class=n-a></a>Boudville N, Ward S, Benaroia M, <i> et al.</i>: Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. <i>Am J Hypertens.</i> 2005; <b>18</b>(10): 1300–5. <a target=xrefwindow id=d7928e1014 href="http://www.ncbi.nlm.nih.gov/pubmed/16202852">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1017 href="https://doi.org/10.1016/j.amjhyper.2004.08.031">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d7928e1026 class=n-a></a>Manolis AJ, Poulimenos LE, Kallistratos MS, <i> et al.</i>: Sympathetic overactivity in hypertension and cardiovascular disease. <i>Curr Vasc Pharmacol.</i> 2014; <b>12</b>(1): 4–15. <a target=xrefwindow id=d7928e1037 href="http://www.ncbi.nlm.nih.gov/pubmed/23905597">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1040 href="https://doi.org/10.2174/15701611113119990140">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733048792"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1049 class=n-a></a>Williams B, MacDonald TM, Morant SV, <i> et al.</i>: Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. <i>Lancet Diabetes Endocrinol.</i> 2018; <b>6</b>(6): 464–75. <a target=xrefwindow id=d7928e1060 href="http://www.ncbi.nlm.nih.gov/pubmed/29655877">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1063 href="https://doi.org/10.1016/S2213-8587(18)30071-8">Publisher Full Text </a> | <a target=xrefwindow id=d7928e1067 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5966620">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733048792">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732726258"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1080 class=n-a></a>Krieger EM, Drager LF, Giorgi DMA, <i> et al.</i>: Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). <i>Hypertension.</i> 2018; <b>71</b>(4): 681–90. <a target=xrefwindow id=d7928e1091 href="http://www.ncbi.nlm.nih.gov/pubmed/29463627">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1094 href="https://doi.org/10.1161/HYPERTENSIONAHA.117.10662">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732726258">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727212599"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1107 class=n-a></a>Zhao D, Liu H, Dong P, <i> et al.</i>: A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. <i>Int J Cardiol.</i> 2017; <b>233</b>: 113–7. <a target=xrefwindow id=d7928e1118 href="http://www.ncbi.nlm.nih.gov/pubmed/28089457">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1121 href="https://doi.org/10.1016/j.ijcard.2016.12.158">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727212599">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730337955"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1135 class=n-a></a>Liu L, Xu B, Ju Y: Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials. <i>Clin Exp Hypertens.</i> 2017; <b>39</b>(3): 257–63. <a target=xrefwindow id=d7928e1143 href="http://www.ncbi.nlm.nih.gov/pubmed/28448185">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1146 href="https://doi.org/10.1080/10641963.2016.1246564">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730337955">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d7928e1159 class=n-a></a>Wang C, Xiong B, Huang J: Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials. <i>Heart Lung Circ.</i> 2016; <b>25</b>(10): 1021–30. <a target=xrefwindow id=d7928e1167 href="http://www.ncbi.nlm.nih.gov/pubmed/27118266">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1170 href="https://doi.org/10.1016/j.hlc.2016.02.016">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d7928e1179 class=n-a></a>Sinnott SJ, Tomlinson LA, Root AA, <i> et al.</i>: Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis. <i>Eur J Prev Cardiol.</i> 2017; <b>24</b>(3): 228–38. <a target=xrefwindow id=d7928e1190 href="http://www.ncbi.nlm.nih.gov/pubmed/27856806">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1193 href="https://doi.org/10.1177/2047487316675194">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734024140"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1202 class=n-a></a>Calhoun DA: Advances in resistant hypertension. <i>Ann Transl Med.</i> 2018; <b>6</b>(15): 294. <a target=xrefwindow id=d7928e1210 href="http://www.ncbi.nlm.nih.gov/pubmed/30211182">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1213 href="https://doi.org/10.21037/atm.2018.07.21">Publisher Full Text </a> | <a target=xrefwindow id=d7928e1216 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6123198">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734024140">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727454653"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1229 class=n-a></a>Schlaich MP: Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension. <i>Am J Hypertens.</i> 2017; <b>30</b>(9): 847–56. <a target=xrefwindow id=d7928e1237 href="http://www.ncbi.nlm.nih.gov/pubmed/28338871">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1240 href="https://doi.org/10.1093/ajh/hpx033">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727454653">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735844819"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1253 class=n-a></a>Bolignano D, Coppolino G: Baroreflex stimulation for treating resistant hypertension: ready for the prime-time? <i>Rev Cardiovasc Med.</i> 2018; <b>19</b>(3): 89–95. <a target=xrefwindow id=d7928e1261 href="http://www.ncbi.nlm.nih.gov/pubmed/31054557">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1264 href="https://doi.org/10.31083/j.rcm.2018.03.3185">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735844819">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734001148"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1278 class=n-a></a>Voora R, Hinderliter AL: Modulation of Sympathetic Overactivity to Treat Resistant Hypertension. <i>Curr Hypertens Rep.</i> 2018; <b>20</b>(11): 92. <a target=xrefwindow id=d7928e1286 href="http://www.ncbi.nlm.nih.gov/pubmed/30194545">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1289 href="https://doi.org/10.1007/s11906-018-0893-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734001148">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737425353"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1302 class=n-a></a>Schlaich MP, Azzam O, Sata Y: Hypertension on the ROX: Durable Blood Pressure Lowering With Central Iliac Arteriovenous Anastomosis. <i>Hypertension.</i> 2017; <b>70</b>(6): 1084–6. <a target=xrefwindow id=d7928e1310 href="http://www.ncbi.nlm.nih.gov/pubmed/29061721">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1313 href="https://doi.org/10.1161/HYPERTENSIONAHA.117.10246">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737425353">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1157905"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1326 class=n-a></a>Krum H, Schlaich M, Whitbourn R, <i> et al.</i>: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. <i>Lancet.</i> 2009; <b>373</b>(9671): 1275–81. <a target=xrefwindow id=d7928e1337 href="http://www.ncbi.nlm.nih.gov/pubmed/19332353">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1340 href="https://doi.org/10.1016/S0140-6736(09)60566-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1157905">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6522956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1353 class=n-a></a>Symplicity HTN-2 Investigators, Esler MD, Krum H, <i> et al.</i>: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. <i>Lancet.</i> 2010; <b>376</b>(9756): 1903–9. <a target=xrefwindow id=d7928e1364 href="http://www.ncbi.nlm.nih.gov/pubmed/21093036">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1367 href="https://doi.org/10.1016/S0140-6736(10)62039-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6522956">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718329296"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1380 class=n-a></a>Bhatt DL, Kandzari DE, O'Neill WW, <i> et al.</i>: A controlled trial of renal denervation for resistant hypertension. <i>N Engl J Med.</i> 2014; <b>370</b>(15): 1393–401. <a target=xrefwindow id=d7928e1391 href="http://www.ncbi.nlm.nih.gov/pubmed/24678939">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1394 href="https://doi.org/10.1056/NEJMoa1402670">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718329296">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d7928e1407 class=n-a></a>Papademetriou V, Stavropoulos K, Doumas M, <i> et al.</i>: Now That Renal Denervation Works, How Do We Proceed? <i>Circ Res.</i> 2019; <b>124</b>(5): 693–5. <a target=xrefwindow id=d7928e1418 href="http://www.ncbi.nlm.nih.gov/pubmed/30817252">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1421 href="https://doi.org/10.1161/CIRCRESAHA.119.314695">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730367936"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1431 class=n-a></a>Townsend RR, Mahfoud F, Kandzari DE, <i> et al.</i>: Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet.</i> 2017; <b>390</b>(10108): 2160–70. <a target=xrefwindow id=d7928e1442 href="http://www.ncbi.nlm.nih.gov/pubmed/28859944">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1445 href="https://doi.org/10.1016/S0140-6736(17)32281-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730367936">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733277917"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1458 class=n-a></a>Kandzari DE, Böhm M, Mahfoud F, <i> et al.</i>: Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet.</i> 2018; <b>391</b>(10137): 2346–55. <a target=xrefwindow id=d7928e1469 href="http://www.ncbi.nlm.nih.gov/pubmed/29803589">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1472 href="https://doi.org/10.1016/S0140-6736(18)30951-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733277917">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733277916"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1485 class=n-a></a>Azizi M, Schmieder RE, Mahfoud F, <i> et al.</i>: Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet.</i> 2018; <b>391</b>(10137): 2335–45. <a target=xrefwindow id=d7928e1496 href="http://www.ncbi.nlm.nih.gov/pubmed/29803590">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1499 href="https://doi.org/10.1016/S0140-6736(18)31082-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733277916">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734755117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1512 class=n-a></a>Fengler K, Rommel KP, Blazek S, <i> et al.</i>: A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). <i>Circulation.</i> 2019; <b>139</b>(5): 590–600. <a target=xrefwindow id=d7928e1523 href="http://www.ncbi.nlm.nih.gov/pubmed/30586691">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1526 href="https://doi.org/10.1161/CIRCULATIONAHA.118.037654">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734755117">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725326211"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1539 class=n-a></a>Lobo MD, Sobotka PA, Stanton A, <i> et al.</i>: Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. <i>Lancet.</i> 2015; <b>385</b>(9978): 1634–41. <a target=xrefwindow id=d7928e1550 href="http://www.ncbi.nlm.nih.gov/pubmed/25620016">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1553 href="https://doi.org/10.1016/S0140-6736(14)62053-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725326211">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732029403"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1566 class=n-a></a>Lobo MD, Ott C, Sobotka PA, <i> et al.</i>: Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial. <i>Hypertension.</i> 2017; <b>70</b>(6): 1099–105. <a target=xrefwindow id=d7928e1577 href="http://www.ncbi.nlm.nih.gov/pubmed/29061728">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1580 href="https://doi.org/10.1161/HYPERTENSIONAHA.117.10142">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732029403">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732657761"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1594 class=n-a></a>Devgun J, Jobanputra YB, Arustamyan M, <i> et al.</i>: Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure. <i>Heart Fail Rev.</i> 2018; <b>23</b>(4): 507–16. <a target=xrefwindow id=d7928e1605 href="http://www.ncbi.nlm.nih.gov/pubmed/29430580">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1608 href="https://doi.org/10.1007/s10741-018-9680-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732657761">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733213475"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1621 class=n-a></a>van Kleef MEAM, Bates MC, Spiering W: Endovascular Baroreflex Amplification for Resistant Hypertension. <i>Curr Hypertens Rep.</i> 2018; <b>20</b>(5): 46. <a target=xrefwindow id=d7928e1629 href="http://www.ncbi.nlm.nih.gov/pubmed/29744599">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1632 href="https://doi.org/10.1007/s11906-018-0840-8">Publisher Full Text </a> | <a target=xrefwindow id=d7928e1635 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5942348">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733213475">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725274930"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1648 class=n-a></a>Bisognano JD, Bakris G, Nadim MK, <i> et al.</i>: Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. <i>J Am Coll Cardiol.</i> 2011; <b>58</b>(7): 765–73. <a target=xrefwindow id=d7928e1659 href="http://www.ncbi.nlm.nih.gov/pubmed/21816315">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1662 href="https://doi.org/10.1016/j.jacc.2011.06.008">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725274930">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735412948"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1675 class=n-a></a>Lohmeier TE, Hall JE: Device-Based Neuromodulation for Resistant Hypertension Therapy. <i>Circ Res.</i> 2019; <b>124</b>(7): 1071–93. <a target=xrefwindow id=d7928e1683 href="http://www.ncbi.nlm.nih.gov/pubmed/30920919">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1686 href="https://doi.org/10.1161/CIRCRESAHA.118.313221">Publisher Full Text </a> | <a target=xrefwindow id=d7928e1689 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6442942">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735412948">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d7928e1702 class=n-a></a>Abraham WT, Zile MR, Weaver FA, <i> et al.</i>: Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC Heart Fail.</i> 2015; <b>3</b>(6): 487–96. <a target=xrefwindow id=d7928e1713 href="http://www.ncbi.nlm.nih.gov/pubmed/25982108">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1716 href="https://doi.org/10.1016/j.jchf.2015.02.006">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d7928e1725 class=n-a></a>Zile M, Lindenfeld J, Weaver FA, <i> et al.</i>: Baroreflex Activation Therapy (BAT) in Patients with Heart Failure and a Reduced Ejection Fraction (HFrEF): The BeAT-HF Trial. 2019. <a target=xrefwindow id=d7928e1730 href="https://ssrn.com/abstract=3452105">Reference Source</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d7928e1740 class=n-a></a>Hoppe UC, Brandt MC, Wachter R, <i> et al.</i>: Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim <i>neo</i> trial. <i>J Am Soc Hypertens.</i> 2012; <b>6</b>(4): 270–6. <a target=xrefwindow id=d7928e1754 href="http://www.ncbi.nlm.nih.gov/pubmed/22694986">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1758 href="https://doi.org/10.1016/j.jash.2012.04.004">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730774357"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e1767 class=n-a></a>Spiering W, Williams B, Van der Heyden J, <i> et al.</i>: Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. <i>Lancet.</i> 2017; <b>390</b>(10113): 2655–61. <a target=xrefwindow id=d7928e1778 href="http://www.ncbi.nlm.nih.gov/pubmed/28870716">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1781 href="https://doi.org/10.1016/S0140-6736(17)32337-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730774357">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d7928e1794 class=n-a></a>ClinicalTrials.gov: Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_US). Accessed February 9, 2020. <a target=xrefwindow id=d7928e1796 href="https://clinicaltrials.gov/ct2/show/NCT01831895">Reference Source</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d7928e1805 class=n-a></a>ClinicalTrials.gov: CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ (CALM-2). Accessed February 9, 2020. <a target=xrefwindow id=d7928e1807 href="https://clinicaltrials.gov/ct2/show/NCT03179800">Reference Source</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d7928e1816 class=n-a></a>Lloberes P, Lozano L, Sampol G, <i> et al.</i>: Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. <i>J Sleep Res.</i> 2010; <b>19</b>(4): 597–602. <a target=xrefwindow id=d7928e1827 href="http://www.ncbi.nlm.nih.gov/pubmed/20545837">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1830 href="https://doi.org/10.1111/j.1365-2869.2010.00839.x">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d7928e1839 class=n-a></a>Logan AG, Perlikowski SM, Mente A, <i> et al.</i>: High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. <i>J Hypertens.</i> 2001; <b>19</b>(12): 2271–7. <a target=xrefwindow id=d7928e1850 href="http://www.ncbi.nlm.nih.gov/pubmed/11725173">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1853 href="https://doi.org/10.1097/00004872-200112000-00022">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d7928e1863 class=n-a></a>Min HJ, Cho YJ, Kim CH, <i> et al.</i>: Clinical Features of Obstructive Sleep Apnea That Determine Its High Prevalence in Resistant Hypertension. <i>Yonsei Med J.</i> 2015; <b>56</b>(5): 1258–65. <a target=xrefwindow id=d7928e1874 href="http://www.ncbi.nlm.nih.gov/pubmed/26256968">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1877 href="https://doi.org/10.3349/ymj.2015.56.5.1258">Publisher Full Text </a> | <a target=xrefwindow id=d7928e1881 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4541655">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d7928e1890 class=n-a></a>Muxfeldt ES, Margallo VS, Guimarães GM, <i> et al.</i>: Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. <i>Am J Hypertens.</i> 2014; <b>27</b>(8): 1069–78. <a target=xrefwindow id=d7928e1901 href="http://www.ncbi.nlm.nih.gov/pubmed/24705438">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1904 href="https://doi.org/10.1093/ajh/hpu023">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d7928e1913 class=n-a></a>Walia HK, Li H, Rueschman M, <i> et al.</i>: Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. <i>J Clin Sleep Med.</i> 2014; <b>10</b>(8): 835–43. <a target=xrefwindow id=d7928e1924 href="http://www.ncbi.nlm.nih.gov/pubmed/25126027">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1927 href="https://doi.org/10.5664/jcsm.3946">Publisher Full Text </a> | <a target=xrefwindow id=d7928e1931 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4106935">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d7928e1940 class=n-a></a>Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, <i> et al.</i>: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. <i>Chest.</i> 2007; <b>131</b>(2): 453–9. <a target=xrefwindow id=d7928e1951 href="http://www.ncbi.nlm.nih.gov/pubmed/17296647">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1954 href="https://doi.org/10.1378/chest.06-1442">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d7928e1963 class=n-a></a>Di Murro A, Petramala L, Cotesta D, <i> et al.</i>: Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. <i>J Renin Angiotensin Aldosterone Syst.</i> 2010; <b>11</b>(3): 165–72. <a target=xrefwindow id=d7928e1974 href="http://www.ncbi.nlm.nih.gov/pubmed/20488824">PubMed Abstract </a> | <a target=xrefwindow id=d7928e1977 href="https://doi.org/10.1177/1470320310366581">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d7928e1986 class=n-a></a>Prejbisz A, Florczak E, Klisiewicz A, <i> et al.</i>: Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. <i>Endokrynol Pol.</i> 2013; <b>64</b>(5): 363–7. <a target=xrefwindow id=d7928e1997 href="http://www.ncbi.nlm.nih.gov/pubmed/24186593">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2000 href="https://doi.org/10.5603/EP.2013.0019">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d7928e2010 class=n-a></a>Friedman O, Bradley TD, Chan CT, <i> et al.</i>: Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. <i>Hypertension.</i> 2010; <b>56</b>(6): 1077–82. <a target=xrefwindow id=d7928e2021 href="http://www.ncbi.nlm.nih.gov/pubmed/21060007">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2024 href="https://doi.org/10.1161/HYPERTENSIONAHA.110.154427">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d7928e2033 class=n-a></a>Chiu KL, Ryan CM, Shiota S, <i> et al.</i>: Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects. <i>Am J Respir Crit Care Med.</i> 2006; <b>174</b>(12): 1378–83. <a target=xrefwindow id=d7928e2044 href="http://www.ncbi.nlm.nih.gov/pubmed/16998093">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2047 href="https://doi.org/10.1164/rccm.200607-927OC">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d7928e2056 class=n-a></a>Redolfi S, Arnulf I, Pottier M, <i> et al.</i>: Effects of venous compression of the legs on overnight rostral fluid shift and obstructive sleep apnea. <i>Respir Physiol Neurobiol.</i> 2011; <b>175</b>(3): 390–3. <a target=xrefwindow id=d7928e2067 href="http://www.ncbi.nlm.nih.gov/pubmed/21220055">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2070 href="https://doi.org/10.1016/j.resp.2011.01.001">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718204805"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e2079 class=n-a></a>Martínez-García MA, Capote F, Campos-Rodríguez F, <i> et al.</i>: Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. <i>JAMA.</i> 2013; <b>310</b>(22): 2407–15. <a target=xrefwindow id=d7928e2090 href="http://www.ncbi.nlm.nih.gov/pubmed/24327037">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2093 href="https://doi.org/10.1001/jama.2013.281250">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718204805">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726683449"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e2106 class=n-a></a>McEvoy RD, Antic NA, Heeley E, <i> et al.</i>: CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. <i>N Engl J Med.</i> 2016; <b>375</b>(10): 919–31. <a target=xrefwindow id=d7928e2117 href="http://www.ncbi.nlm.nih.gov/pubmed/27571048">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2120 href="https://doi.org/10.1056/NEJMoa1606599">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726683449">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732117098"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e2133 class=n-a></a>Whelton PK, Carey RM, Aronow WS, <i> et al.</i>: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension.</i> 2018; <b>71</b>(19): e127–e248. <a target=xrefwindow id=d7928e2144 href="http://www.ncbi.nlm.nih.gov/pubmed/29146535">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2147 href="https://doi.org/10.1016/j.jacc.2017.11.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732117098">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d7928e2161 class=n-a></a>Dudenbostel T, Acelajado MC, Pisoni R, <i> et al.</i>: Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. <i>Hypertension.</i> 2015; <b>66</b>(1): 126–33. <a target=xrefwindow id=d7928e2172 href="http://www.ncbi.nlm.nih.gov/pubmed/25987662">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2175 href="https://doi.org/10.1161/HYPERTENSIONAHA.115.05449">Publisher Full Text </a> | <a target=xrefwindow id=d7928e2179 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4465856">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727222833"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e2188 class=n-a></a>Siddiqui M, Calhoun DA: Refractory versus resistant hypertension. <i>Curr Opin Nephrol Hypertens.</i> 2017; <b>26</b>(1): 14–9. <a target=xrefwindow id=d7928e2196 href="http://www.ncbi.nlm.nih.gov/pubmed/27798457">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2199 href="https://doi.org/10.1097/MNH.0000000000000286">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727222833">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733387499"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7928e2212 class=n-a></a>Velasco A, Siddiqui M, Kreps E, <i> et al.</i>: Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. <i>Hypertension.</i> 2018; <b>72</b>(2): 343–9. <a target=xrefwindow id=d7928e2223 href="http://www.ncbi.nlm.nih.gov/pubmed/29866740">PubMed Abstract </a> | <a target=xrefwindow id=d7928e2226 href="https://doi.org/10.1161/HYPERTENSIONAHA.118.10965">Publisher Full Text </a> | <a target=xrefwindow id=d7928e2230 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6043380">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733387499">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 09 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-169&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-169&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, 54250, Greece<br/> <sup>2</sup> VAMC and George Washington University, Washington, USA<br/> <sup>3</sup> Cardiology, Asklepeion General Hospital, Athens, Attiki, 16673, Greece<br/> <p> <div class=margin-bottom> Michael Doumas <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Konstantinos P Imprialos <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Manolis S Kallistratos <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Athanasios J Manolis <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-169/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 09 Mar 2020, 9:169 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.21669.1">https://doi.org/10.12688/f1000research.21669.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Doumas M <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=23889 data-id=21669 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21669.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-169/v1/pdf?article_uuid=3adf96ce-7b56-49ff-a450-80da1f03d2b5" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.21669.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Doumas M, Imprialos KP, Kallistratos MS and Manolis AJ. Recent advances in understanding and managing resistant/refractory hypertension [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):169 (<a href="https://doi.org/10.12688/f1000research.21669.1" target=_blank>https://doi.org/10.12688/f1000research.21669.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=21669 id=mobile-track-article-signin-21669 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21669?target=/articles/9-169"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23889 /> <input name=articleId type=hidden value=21669 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>David Calhoun</strong>, Vascular Biology and Hypertension Program, University of Alabama at Birmingham, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>George Bakris</strong>, Department of Medicine, ASH Comprehensive Hypertension Center, University of Chicago Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 09 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-169&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-169&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=64850-60819></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=35474-60820></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-169/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>09 Mar 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>David Calhoun</strong>, Vascular Biology and Hypertension Program, University of Alabama at Birmingham, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>George Bakris</strong>, Department of Medicine, ASH Comprehensive Hypertension Center, University of Chicago Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-169&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-169/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding and managing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-169/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-169/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-169/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Doumas M et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-169/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-169",
            templates : {
                twitter : "Recent advances in understanding and managing resistant\/refractory.... Doumas M et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-169/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding and managing resistant\/refractory hypertension", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding and managing resistant\/refractory hypertension", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/21669/23889")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "23889");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "60819": 0,
                           "60820": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "60ced1a7-4fc9-4b9d-81cf-8a3114f2c087";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-169.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-169.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-169.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-169.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-169.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>